NeoTract, Inc., founded in 2004 and headquartered in Pleasanton, California, specializes in medical devices aimed at addressing significant clinical needs. The company's flagship product, the UroLift System, is a minimally invasive permanent implant designed to treat men suffering from benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate. This system offers rapid symptom relief and improved quality of life while preserving normal sexual function, a significant advantage over traditional treatments. NeoTract operates in the medical device market and serves healthcare providers and patients across the USA, Europe, Australia, Canada, Mexico, and South Korea. The company's business model revolves around direct sales and distributor partnerships in key global markets. Revenue is generated through the sale of the UroLift System and related medical devices. NeoTract's innovative approach and clinically proven solutions have led to the treatment of over 100,000 patients, establishing it as a leader in the BPH treatment space.

Keywords: UroLift System, benign prostatic hyperplasia, BPH, minimally invasive, medical devices, prostate treatment, sexual function preservation, global distribution, healthcare providers, clinical innovation.